Lívia Sousa Selected Research

Injections

11/2016

Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lívia Sousa Research Topics

Disease

7	Multiple Sclerosis 02/2024 - 07/2016
6	Relapsing-Remitting Multiple Sclerosis 03/2023 - 12/2014
1	COVID-19 02/2024
1	Sudden Infant Death (SID) 02/2024
1	Chronic Progressive Multiple Sclerosis 03/2023
1	Disease Progression 01/2017
1	Intracranial Hypotension 01/2016
1	Demyelinating Diseases (Demyelinating Disease) 04/2014

Drug/Important Bio-Agent (IBA)

2	Natalizumab (Tysabri)FDA Link 02/2024 - 06/2021
2	Biomarkers (Surrogate Marker)IBA 03/2023 - 02/2022
1	ProteomeIBA 02/2022
1	Proteins (Proteins, Gene)FDA Link 02/2022
1	Fingolimod Hydrochloride (FTY720)FDA Link 03/2021
1	Pharmacological BiomarkersIBA 01/2021
1	Retinaldehyde (Retinal)IBA 01/2018
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2017
1	Matrix Metalloproteinases (MMPs)IBA 01/2017
1	Metalloproteases (Metalloproteinases)IBA 01/2017
1	Indicators and Reagents (Reagents)IBA 11/2016
1	Oligoclonal BandsIBA 04/2014

Therapy/Procedure

6	Therapeutics 02/2024 - 12/2014
1	Plasma Exchange 01/2018
1	Injections 11/2016
1	Epidural Blood Patch 01/2016